Contemporary rends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States


Allard C. B. , Gelpi-Hammerschmidt F., Harshman L. C. , Choueiri T. K. , Faiena I., Modi P., ...More

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.33, no.11, 2015 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 11
  • Publication Date: 2015
  • Doi Number: 10.1016/j.urolonc.2015.06.014
  • Title of Journal : UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
  • Keywords: High-dose interleukin-2, Immunotherapy, Renal cell carcinoma, Kidney cancer, Therapy trends, Toxicity, INTERFERON-ALPHA, DOUBLE-BLIND, CANCER, STATISTICS, SURVIVAL, ANTIBODY, MELANOMA, SAFETY

Abstract

Background: Targeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the IT era.